Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for chronic lymphocytic leukaemia and lymphoproliferative disorders.
Department of Haematology, CLL Unit, Sydney, Australia. mulligan@sydney.edu.au.|Kolling Research Institute, University of Sydney, Sydney, Australia. mulligan@sydney.edu.au.
Stephen P
SP
Mulligan
Kolling Research Institute, University of Sydney, Sydney, Australia.|Department of Haematology, Haemostasis Unit, Sydney, Australia.
Christopher M
CM
Ward
Kolling Research Institute, University of Sydney, Sydney, Australia.|Department of Cardiology, Electrophysiology Unit, Sydney, Australia.
David
D
Whalley
Kolling Research Institute, University of Sydney, Sydney, Australia.|Department of Clinical Pharmacology and Aged Care, Royal North Shore Hospital, Sydney, Australia.
Sarah N
SN
Hilmer
D000225:Adenine / Q000031:analogs & derivatives; D000925:Anticoagulants; D001281:Atrial Fibrillation; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell; D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; D012307:Risk Factors; D020521:Stroke; D014859:Warfarin
D000925:Anticoagulants; D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D014859:Warfarin; D000225:Adenine
atrial fibrillation; chronic lymphocytic leukaemia; drug interactions; ibrutinib; stroke prophylaxis